CELC vs. CDNA, CSTL, SERA, FLGT, BDSX, VRDN, ENZ, RNLX, XGN, and DMTK
Should you be buying Celcuity stock or one of its competitors? The main competitors of Celcuity include CareDx (CDNA), Castle Biosciences (CSTL), Sera Prognostics (SERA), Fulgent Genetics (FLGT), Biodesix (BDSX), Viridian Therapeutics (VRDN), Enzo Biochem (ENZ), Renalytix (RNLX), Exagen (XGN), and DermTech (DMTK). These companies are all part of the "medical laboratories" industry.
CareDx (NASDAQ:CDNA) and Celcuity (NASDAQ:CELC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability.
63.3% of Celcuity shares are held by institutional investors. 4.2% of CareDx shares are held by company insiders. Comparatively, 24.3% of Celcuity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
CareDx received 102 more outperform votes than Celcuity when rated by MarketBeat users. Likewise, 66.72% of users gave CareDx an outperform vote while only 66.60% of users gave Celcuity an outperform vote.
Celcuity has a net margin of 0.00% compared to Celcuity's net margin of -66.59%. Celcuity's return on equity of -51.29% beat CareDx's return on equity.
In the previous week, CareDx had 11 more articles in the media than Celcuity. MarketBeat recorded 17 mentions for CareDx and 6 mentions for Celcuity. CareDx's average media sentiment score of 0.87 beat Celcuity's score of 0.62 indicating that Celcuity is being referred to more favorably in the news media.
CareDx has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Celcuity has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.
Celcuity has lower revenue, but higher earnings than CareDx. Celcuity is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.
CareDx presently has a consensus target price of $14.00, indicating a potential downside of 5.60%. Celcuity has a consensus target price of $29.00, indicating a potential upside of 72.31%. Given CareDx's stronger consensus rating and higher probable upside, analysts clearly believe Celcuity is more favorable than CareDx.
Summary
Celcuity beats CareDx on 9 of the 17 factors compared between the two stocks.
Get Celcuity News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CELC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celcuity Competitors List
Related Companies and Tools
